The crystal structures of prostaglandin F synthase (PGF) from both Leishmania major and Trypanosoma cruzi with and without their cofactor NADP have been determined to resolutions of 2.6 Å for T. cruzi PGF, 1.25 Å for T. cruzi PGF with NADP, 1.6 Å for L. major PGF and 1.8 Å for L. major PGF with NADP. These structures were determined by molecular replacement to a final R factor of less than 18.6% (R free of less than 22.9%). PGF in the infectious protozoa L. major and T. cruzi is a potential therapeutic target. molecular parasitology 610 Moen et al. Prostaglandin F synthase Acta Cryst. (2015). F71, 609-614
Introduction
The Seattle Structural Genomics Center for Infectious Disease (SSGCID) is a consortium funded by NIAID to elucidate solutions of protein structures from biodefense organisms, as well as those causing emerging and re-emerging diseases. Prostaglandin F synthase (PGF) from the infectious protozoa Leishmania major (UniProt P22045) and Trypanosoma cruzi (UniProt Q4DJ07) have been identified by the TDR target database as being essential proteins for both organisms and potential therapeutic targets (Magariñ os et al., 2012) . PGF is an oxidoreductase enzyme that catalyzes the reaction (5Z,13E)-(15S)-9,11,15-trihydroxyprosta-5,13dienoate + NADP + Ð (5Z,13E)-(15S)-9,15-dihydroxy-11oxoprosta-5,13-dienoate + NADPH + H + . PGF specifically acts on the CH-OH of the proton donor with NADP as the acceptor (Watanabe et al., 1981) . In humans, PGF (UniProt P42330) can interconvert active androgens, estrogens and progestins with their cognate inactive metabolites (Qin et al., 1993) . In protozoa, PGF is involved in essential lipidmetabolism pathways. The protozoa L. major, the causative agent of leishmaniasis, and T. cruzi, the causative agent of Chagas disease, both affect millions of people and represent major public health issues. Both diseases have very limited treatment options and drug resistance is prevalent (Minodier & Parola, 2007; Buckner et al., 1998) . Here, we describe the structures of PGF with and without NADP in both organisms and the structural differences between the bound and the unbound state of the enzyme with regard to its cofactor. Previous structural work on PGFs has been performed for Homo sapiens PGF (PDB entry 1ry8; Komoto et al., 2004) and
# 2015 International Union of Crystallography PGF from T. brucei, another protozoan (PDB entry 1vbj; T. Inoue, unpublished work). PDB entry 1ry8 is a useful structure for determining the selectivity of potential compounds against human PGF, which will need to be taken into consideration (Komoto et al., 2004) . PDB entry 1vbj was used as a model for molecular replacement and has sequence identities of 60% to T. cruzi PGF and 61% to L. major PGF ( Fig. 1 ).
Materials and methods

Cloning, expression and purification
The gene encoding PGF from L. major strain Friedlin (SSGCID ID LemaA.00019.a.B1) was PCR-amplified from genomic DNA that was kindly provided by Frederick S. Buckner. The gene was amplified using the following primer sequences: FWD primer 5 0 -CTCACCACCACCACCACCA-TATGGCTGGCGTTGATAAGGCAAT-3 0 and REV primer 5 0 -ATCCTATCTTACTCACTTAGAACTGCGCCTCATCA-GGGTC-3 0 . Thermal cycling conditions were 371 K for 180 s followed by 34 cycles of 371 K for 30 s, 346 K for 330 s, 360 K for 360 s and 360 K for 360 s followed by a final extension at 351 K for 300 s.
Likewise, the gene encoding PGF from T. cruzi strain CL Brener (SSGCID ID TrcrA.00019.a.B1) was PCR-amplified using the following primer sequences: FWD primer 5 0 -CTCACCACCACCACCACCATATGAATTGCAATTACA-ACTGTGTGAC-3 0 and REV primer 5 0 -ATCCTATCTTACT-CACTTACTCCTCTCCACCAGGGAAAAAAT-3 0 . Thermal cycling conditions were 367 K for 180 s followed by 30 cycles of 367 K for 30 s, 333 K for 60 s and 345 K for 120 s followed by a final extension at 345 K for 600 s.
Purified PCR products from both PGF constructs were cloned into a BG1861 expression vector (pET-14b derivative)
Figure 1
An alignment of PGFs from H. sapiens (PDB entry 1ry8), T. cruzi (PDB entries 4fzi and 4gie) and L. major (PDB entries 4f40 and 4g5d) with residues that match highlighted in green, residues that are conserved highlighted in blue and residues that are similar highlighted in yellow; residues that are different are not highlighted. The two protozoan proteins have 74% sequence identity to each other. This figure was generated using GeneComposer (Lorimer et al., 2011) . were collected and concentrated to 20 mg ml À1 using a polyethersulfone concentrator with an appropriate molecularweight cutoff. Protein concentrations were determined with a UV spectrophotometer using the theoretical extinction coefficients determined using the online tool at http:// web.expasy.org/protparam/. The final samples were divided into 100 ml aliquots and flash-frozen in liquid nitrogen.
Protein crystallization
All protein crystallization experiments were performed using the sitting-drop vapor-diffusion method in Compact 300 (Rigaku Reagents) crystallization trays at 289 K. Crystallization experiments consisted of 400 nl protein solution and 400 nl precipitant solution in the sample well equilibrated against 80 ml precipitant solution in the reservoir well. Detailed crystallization conditions including protein concen-trations and cofactor concentrations are available in Table 1 . All crystals formed in 2-4 weeks.
The crystals were harvested using mounted cryoloops (Hampton Research) and flash-cooled in pucks immersed in liquid nitrogen for storage until X-ray diffraction data collection. Data were either collected on our in-house FR-E+ SuperBright X-ray source (Rigaku) or on Advanced Light Source (ALS) beamlines 5.0.1 and 5.0.3. All X-ray reflection data were indexed, integrated and scaled using XDS and XSCALE (Kabsch, 2010a,b) . Data statistics for all data sets are available in Table 2 .
Data collection and processing
The diffraction data sets for PDB entries 4gie and 4f40 were collected on ALS beamline 5.0.1 with an ADSC Quantum 315 CCD detector. The diffraction data set for PDB entry 4fzi was collected on ALS beamline 5.0.3 with an ADSC Quantum 315 CCD detector. The diffraction data set for PDB entry 4g5d was collected in-house with a Rigaku FR-E+ SuperBright generator using a Rigaku 944+ CCD detector. All data sets were collected at 100 K. The X-ray data were reduced with XDS and XSCALE. Details of the data collections are summarized in Table 2 .
Structure solution and refinement
Phases for structure determination were obtained via The overall fold of (a) T. cruzi PGF (PDB entry 4fz1) and (b) T. cruzi PGF with NADP bound (PDB entry 4gie). The appearance of the disordered loop in the NADP-bound structure can be seen. monomers were used as the search model in molecular replacement. All other structures were solved by molecular replacement using PDB entry 4f40 as the search model. Initial molecular model building was performed using ARP/wARP (Langer et al., 2008) . Models were refined against the X-ray reflection data using either PHENIX (Adams et al., 2010) and REFMAC (Murshudov et al., 2011) interspersed with rounds of model building using Coot (Emsley et al., 2010) . TLS groups were chosen using phenix.find_tls_groups within the PHENIX suite (Afonine et al., 2012) . Figures containing molecular graphics were prepared using PyMOL (Schrö dinger). Solution and refinement statistics can be found in Table 3 .
Results and discussion
As part of the efforts of the SSGCID as a high-throughput structure-determination consortium our goal is to help enable, through structure determination, therapeutic development or function determination of infectious disease proteins (Myler et al., 2009) . For each of the two proteins two crystallization trials were set up before finding usable crystals. For LemaA.00019.a.B1 JCSG+ and PACT were used. For TrcrA.00019.a.B1 the Morpheus and Index screens were used. The prostaglandin F synthases from both L. major and T. cruzi represent classic NADP-binding Rossmann-fold structural motifs, as are common in oxidoreductases (Rao & Rossmann, 1973) . These high-resolution structures show that the same loop in LemaA.00019.a.B1] has significant movement between the apoenzyme and holoenzyme (Fig. 2) . The L. major loop becomes ordered and a key interaction with one of the phosphates of NADP at Gln202 is likely to stabilize this region ( Figs. 3a and 3c) . Similarly, T. cruzi Ser193 makes an interaction with one of the phosphates of NADP that is likely to stabilize the loop in a significantly different orientation ( Figs. 3b and 3d ). In the human PGF structure (PDB entry 1ry8), Ser221 makes a hydrogen-bond interaction with one of the phosphates of NADP via the backbone amide and is the equivalent residue to Ser193 and Gln202 in the T. cruzi and L. major structures, respectively. The pairwise C r.m.s.d. between the two apo structures of protozoan PGFs is 0.400 Å . The r.m.s.d.s between the two cofactor-bound structures of protozoan PGFs is 0.409 Å . The structures of these proteins with and without their cofactor provide a more robust and clearer understanding of potential binding sites for not only the cofactor but also for the substrate and any subsequent molecules designed for these proteins. Their structural similarity could be useful as a template for structure-based drugdesign efforts for therapeutics that target both L. major and T. cruzi. However, the high structural similarity of human PGF (PDB entry 1ry8), with a C r.m.s.d. of 0.656 Å for PDB entry 4gie and 0.729 Å for PDB entry 4g5d, represents a potential hurdle for the design of selective molecules even though the sequence identity between human PDF and the T. cruzi and L. major PGFs is 36 and 37%, respectively. As the interaction of residue Ser221 with the cofactor takes place through the backbone amide, the difference in the amino acid at this location in the binding pocket is not likely to be very important.
